Comparison study between insulin glargine and decludec on the glucose fluctuation in Type 2 diabetic patients treated with basal insulin and oral hypoglycemic agents.
Not Applicable
- Conditions
- Type 2 diabetic patients
- Registration Number
- JPRN-UMIN000012138
- Lead Sponsor
- Kyorin University of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
patients with liver or renal dysfunction and obese patienst(BMI over than 35)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie insulin glargine and decludec's effects on glucose fluctuation in Type 2 diabetes?
How does decludec compare to insulin glargine in reducing postprandial glucose variability among Type 2 diabetic patients on basal insulin and oral agents?
Which biomarkers (e.g., HbA1c, C-peptide) predict differential response to insulin glargine versus decludec in JPRN-UMIN000012138?
What are the hypoglycemia risk profiles and management strategies for decludec versus insulin glargine in Type 2 diabetes patients?
How does decludec's efficacy in glucose control compare to other long-acting insulins like insulin detemir or insulin degludec in Type 2 diabetes?